Abstract mRNA vaccines have emerged as highly effective strategies in the prophylaxis and
treatment of diseases, thanks largely although not totally to their extraordinary performance …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Lipid nanoparticles (LNPs) have recently emerged as a powerful and versatile clinically
approved platform for nucleic acid delivery, specifically for mRNA vaccines. A major …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable
diseases and genetic disorders by regulating disease-related gene expression. The …

Cancer is a leading public health problem worldwide. Its treatment remains a daunting
challenge, although significant progress has been made in existing treatments in recent …

In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …